Opaleye Management Inc. Inhibrx, Inc. Transaction History

Opaleye Management Inc.

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2022 Nov 14, 2022	SELL	$11.58 - $24.73 $3.44 Million - $7.35 Million	-297,300 Reduced 50.39%	292,700 $5.25 Million
Q2 2022 Aug 15, 2022	BUY	$8.52 - $25.26 $5.03 Million - $14.9 Million	590,000 New	590,000 $6.7 Million

18.6K

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $603M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

Get notified when there are updates to the investment portfolio of Opaleye Management Inc., based on Form 13F filings with the SEC.

Stay updated on Opaleye Management Inc. with notifications on news.